Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Genprex Inc GNPX

Healthcare Biotechnology
Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. The Company’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:GNPX)

Genprex to Participate at BIO Europe Spring 2025

PR Newswire 11 days ago

Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System

PR Newswire February 19, 2025

Genprex Provides Update on Diabetes Gene Therapy Program

PR Newswire February 18, 2025

Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer

PR Newswire February 13, 2025

Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

PR Newswire January 23, 2025

Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

PR Newswire January 6, 2025

Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

PR Newswire December 16, 2024

Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer

PR Newswire November 20, 2024

Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting

PR Newswire November 5, 2024
View More News ››

Opinion & Analysis (NDAQ:GNPX)

Genprex Shares Soar 250% on FDA Fast Track Designation for Lung Cancer Drug

Streetwise Reports January 22, 2020
View More Opinion ››

Bullboard Posts (NDAQ:GNPX)

Genprex to Participate in 2024 BIO Europe Conference

NEWS: $GNPX Genprex to Participate in 2024 BIO Europe ConferenceGenprex to Participate in 2024 BIO Europe Conference PR Newswire AUSTIN,...
whytestocks - October 31, 2024

Genprex Collaborators Present Positive Preclinical Data on t

JUST IN: $GNPX Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa&#xAE; Gene Therapy for the Treatment of...
whytestocks - October 28, 2024

Genprex Receives Safety Review Committee Approval to Advance

Just In: $GNPX Genprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3...
whytestocks - October 15, 2024

Genprex Featured in CEO/CFO Magazine Discussing Novel Gene T

Breaking News: $GNPX Genprex Featured in CEO/CFO Magazine Discussing Novel Gene Therapies for Cancer and DiabetesGenprex Featured in CEO...
whytestocks - September 23, 2024

Genprex Announces Formation of Mesothelioma Clinical Advisor

Breaking News: $GNPX Genprex Announces Formation of Mesothelioma Clinical Advisory BoardGenprex Announces Formation of Mesothelioma...
whytestocks - September 19, 2024

$GNPX News!

$GNPX @genprex Genprex Inc Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors https://www.genprex...
MasterJedijazz - May 13, 2024
View more Bullboard ››

Coelacanth Energy Inc.

Coelacanth Energy Inc.

Coelacanth Energy Inc. is a Montney-focused oil and natural gas exploration and development company, with lands located in ...
View More »